Your browser doesn't support javascript.
loading
Determining the ERK-regulated phosphoproteome driving KRAS-mutant cancer.
Klomp, Jennifer E; Diehl, J Nathaniel; Klomp, Jeffrey A; Edwards, A Cole; Yang, Runying; Morales, Alexis J; Taylor, Khalilah E; Drizyte-Miller, Kristina; Bryant, Kirsten L; Schaefer, Antje; Johnson, Jared L; Huntsman, Emily M; Yaron, Tomer M; Pierobon, Mariaelena; Baldelli, Elisa; Prevatte, Alex W; Barker, Natalie K; Herring, Laura E; Petricoin, Emanuel F; Graves, Lee M; Cantley, Lewis C; Cox, Adrienne D; Der, Channing J; Stalnecker, Clint A.
Affiliation
  • Klomp JE; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Diehl JN; Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Klomp JA; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Edwards AC; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Yang R; Cell Biology and Physiology Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Morales AJ; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Taylor KE; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Drizyte-Miller K; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Bryant KL; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Schaefer A; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Johnson JL; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Huntsman EM; Lineberger Comprehensive Cancer Center; University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Yaron TM; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Pierobon M; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
  • Baldelli E; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
  • Prevatte AW; Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
  • Barker NK; Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
  • Herring LE; Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.
  • Petricoin EF; Meyer Cancer Center, Weill Cornell Medicine, New York, NY 10065, USA.
  • Graves LM; Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10021, USA.
  • Cantley LC; Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA.
  • Cox AD; School of Systems Biology, George Mason University, Fairfax, VA 22030, USA.
  • Der CJ; School of Systems Biology, George Mason University, Fairfax, VA 22030, USA.
  • Stalnecker CA; UNC Michael Hooker Proteomics Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Science ; 384(6700): eadk0850, 2024 Jun 07.
Article de En | MEDLINE | ID: mdl-38843329
ABSTRACT
To delineate the mechanisms by which the ERK1 and ERK2 mitogen-activated protein kinases support mutant KRAS-driven cancer growth, we determined the ERK-dependent phosphoproteome in KRAS-mutant pancreatic cancer. We determined that ERK1 and ERK2 share near-identical signaling and transforming outputs and that the KRAS-regulated phosphoproteome is driven nearly completely by ERK. We identified 4666 ERK-dependent phosphosites on 2123 proteins, of which 79 and 66%, respectively, were not previously associated with ERK, substantially expanding the depth and breadth of ERK-dependent phosphorylation events and revealing a considerably more complex function for ERK in cancer. We established that ERK controls a highly dynamic and complex phosphoproteome that converges on cyclin-dependent kinase regulation and RAS homolog guanosine triphosphatase function (RHO GTPase). Our findings establish the most comprehensive molecular portrait and mechanisms by which ERK drives KRAS-dependent pancreatic cancer growth.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Phosphoprotéines / Protéines proto-oncogènes p21(ras) / Mitogen-Activated Protein Kinase 1 / Protéome / Mitogen-Activated Protein Kinase 3 Limites: Animals / Humans Langue: En Journal: Sci. (N.Y., N.Y.) / Science Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs du pancréas / Phosphoprotéines / Protéines proto-oncogènes p21(ras) / Mitogen-Activated Protein Kinase 1 / Protéome / Mitogen-Activated Protein Kinase 3 Limites: Animals / Humans Langue: En Journal: Sci. (N.Y., N.Y.) / Science Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique